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bstract
Protein kinases are essential components of various signaling pathways and represent attractive targets for therapeutic interven-
ions. Kinase inhibitors are currently used to treat malignant tumors, as well as autoimmune diseases, due to their involvement in
mmune cell signaling. In this study, three-dimensional quantitative structure–activity relationship (3D-QSAR) analyses, includ-
ng Multiple Linear Regression (MLR), Partial Least Squares (PLS), Multiple Non-Linear Regression (MNLR), Artificial Neural
etwork (ANN) and cross-validation analyses, were performed on a set of P38 MAP kinases as anti-cancer agents. This method,
hich is based on molecular modeling (molecular mechanics, Hartree-Fock (HF)), was used to determine the structural parameters,
lectronic properties, and energy associated with the molecules we examined. MLR, PLS, and MNLR analyses were performed
n 46 protein P38 MAP kinase analogs to determine the relationships between molecular descriptors and the anti-cancer prop-
rties of the P38 MAP kinase analogs. The MLR model was validated by the external validation and standardization approach.
he ANN, given the descriptors obtained from the MLR, exhibited a correlation coefficient close to 0.94. The predicted model
as confirmed by two methods, leave-one-out (LOO) cross-validation and scrambling (or Y-randomization). We observed a high
orrelation between predicted and experimental activity, thereby both validating and demonstrating the high quality of the QSAR
odel that we described.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Taibah University. This is an open access article under
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Intracellular signaling pathways facilitate the trans-
duction of cellular signals that are initiated when
extracellular ligands bind to receptors on the plasmadels to predict anti-cancer activity on a series of protein P38
g/10.1016/j.jtusci.2016.05.006
behalf of Taibah University. This is an open access article under the
membrane. One critical intracellular signaling pathway
is the mitogen-associated protein (MAP) kinase path-
way. Protein kinases, enzymes with over 500 members
encoded within the human genome, represent one of the
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largest families of proteins. Protein kinases participate
in many signal transduction pathways that regulate all
aspects of cellular function. Most cancers are associ-
ated with deregulation of protein kinase function, which
can occur as a result of genetic mutations that lead to
their over-expression or constitutive activation. Protein
kinases serve a critical role in many other diseases as
well [1].
Because MAPKs perform crucial functions in many
signaling pathways essential to cellular responses, they
are very highly genetically conserved across species.
Normal MAPK signaling plays a central role in the reg-
ulation of numerous biological functions necessary for
physiological processes, and dysregulation of this path-
way leads to several pathologies [2–4]. P38 MAPKs
regulate the differentiation of several cell types by
directly phosphorylating and modulating the activity of
transcription factors involved in differentiation. In addi-
tion, they can stimulate chromatin remodeling to allow
transcription of genes related to differentiation and to
stabilize mRNA encoding regulators of differentiation
[5].
Kinase inhibitors are drugs that inhibit the function
of a kinase. Several items set to have their devoted dur-
ing the past year. Developing synthetic kinase inhibitors
involves the use of chemical synthesis to build a “small
molecule” that blocks an important site on a kinase and
arrests its function. Kinase inhibitors, which are denoted
by the “tinib” (suffix) in the BOM, may block kinase
function by different mechanisms. The most common
mechanism is blockage of the ATP-binding site, which
prevents the binding of phosphate residues necessary
for phosphorylation. Such kinase inhibitors are used to
target tumor cells or vascular endothelial cells as anti-
cancer agents. This practice is called “targeted therapy”
because kinase inhibitors have a specific, known func-
tion, as opposed to conventional chemotherapy which
acts indiscriminately within the rapidly dividing cells of
tumor tissues [6–8].
Drug discovery is a long and complex process.
Quantitative structure–activity relationship (QSAR)
methodology is an essential tool in modern medicinal
chemistry that is used to find a correlation between bio-
logical activities measured for a panel of compounds and
molecular descriptors. QSAR modern began in the early
1960 but it is has 1841 The first investigations into the
correlation of biological activity and physicochemical
properties began nearly 60 years before the importantPlease cite this article in press as: E.G. Hadaji, et al. 3D-QSAR mo
MAP kinase inhibitors, J. Taibah Univ. Sci. (2016), http://dx.doi.or
work of Overton and Meyer linking aquatic toxicity to
lipid partitioning in water. In 1962 came the seminal
work of Corwin Hansch and colleagues, which aroused
great interest in the field of predicting biological activity PRESS
rsity for Science xxx (2016) xxx–xxx
of molecules. Since then, the use of QSAR has contin-
ued to grow, with more than 1,400 publications produced
annually since 2011 [9]. QSAR techniques are based
on the concept that similar structures have similar prop-
erties and that the more differences there are between
molecules, the harder it is to correlate their physico-
chemical properties and biological activities, whereas
such correlations between highly similar molecules are
much easier [10]. The application of QSAR to molec-
ular modeling and drug design has led to the inclusion
of tools developed in the field of computational chem-
istry. Computational chemistry addresses using various
chemometric tools to determine the quantitative corre-
lation between molecular structures and activities. The
importance of the QSAR technique lies in its ability (1)
to determine the essential structural requirements for a
molecule to exhibit a given responses and to (2) predict
the activity of untested molecules followed by the design
of virtual libraries [11].
QSAR studies have been used to identify important
structural features responsible for anti-cancer activity of
drugs [12]. Quantitative structure–activity relationships
are a significant factor in drug design; consequently, it
is quite evident why a many users of QSAR [13,14]
are located in industrial research units. Thus, classical
QSAR and 3D-QSAR are highly active areas of research
in the field of drug design [15,16]. The basis for differ-
ent quantitative structure–activity relationship (QSAR)
methods is the ‘description’ of the molecular structures
by means of numbers. Today, a large number of molecu-
lar descriptors have been developed for be use in QSAR
studies [17–21].
Our main objective in this work was to develop a
novel model for studying the relationship between the
structure and anti-cancer activity of P38 MAPKs and
their derivatives.
In this study, Multiple Linear Regression (MLR),
Partial Least Squares (PLS), Multiple Non-Linear
Regression (MNLR), Artificial Neural Network (ANN)
and cross validation analyses were applied to a series
of P38 MAP Kinase Inhibitors in order to develop a
3D-QSAR model to reliably predict anti-cancer activity.
2.  Materials  and  methods
2.1.  Experimental  data
The experimental pIC50s of P38 MAP kinasedels to predict anti-cancer activity on a series of protein P38
g/10.1016/j.jtusci.2016.05.006
inhibitors have been reported in recent publications [22].
We transformed the IC50 values from units of molarity
(M) to pIC50 (−log IC50) in order to provide numeri-
cally larger data values, listed in Table 1.
Please cite this article in press as: E.G. Hadaji, et al. 3D-QSAR models to predict anti-cancer activity on a series of protein P38
MAP kinase inhibitors, J. Taibah Univ. Sci. (2016), http://dx.doi.org/10.1016/j.jtusci.2016.05.006
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Table 1
Study compounds and radicals.
Compound R PIC50
N
F F
O
R
F
F
1 S 6.49
2 O 6.72
3 CH2 7.03
4 NHCH2 6.06
5 C2H2 6.05
6 C2H4 6.31
NH
NH
F F
O
R
7
F
F
O
6.14
8
N
O
>5
9
O
5.89
10
O
6.80
11
O
>5
12
HN
5.89
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Table 1 (Continued)
Compound R PIC50
13
F
HN
F
6.14
14
HN
F
F
8.46
15
HN
7.70
16 6.32
17 5.84
NH
NH
F F
O
O
R1
R2
R3
R4
R5
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Table 1 (Continued)
Comp. R1 R2 R3 R4 R5 PIC50
18 Cl – – H H 7.36
19 Me – – H H 7.04
20 OMe – – H H 7.09
21 CF3 – – H H 5.62
22 – F – H H 6.38
23 – Cl – H H 6.62
24 – Me – H H 7.15
25 – OMe – H H >5
26 – CF3 – H H >5
27 – – F H H 7.32
28 – – Cl H H 7.1
29 – – Me H H 6.59
30 – – OMe H H >5
31 – – CF3 H H >5
32 F F – – – 7.49
33 Cl Cl – – – 7.49
34 F – Cl – – 7.96
35 Cl – F – – 7.85
36 Cl Cl – – – 7.52
37 F – – Cl – 6.89
38 Cl – – Cl – 6.55
39 F – – – F 7.02
40 Cl – – – Cl 7.05
41 F – F – F 6.70
42 Cl – F – Cl 7.17
43 F F F F F 5.37
44 – F F – – 6.67
45 – Cl F – – 6.85
4 Cl 
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In this work, we analyzed a series of molecules com-
rised of 46 P38 MAP Kinase derivatives (Table 1) in
rder to study the relationship between anti-cancer activ-
ty and molecular structure.
.2.  Validation  of  QSAR  models
To assess the performance of the regression model
ithout bias, an independent set of compounds was gen-
rated to test the QSAR model. The model was first
eveloped using the training set of compounds, then the
est set of compounds were used to assess the perfor-
ance of the final extrapolation model. The test set was
andomly selected using 1 out of 4 of all compounds
tudied (25%), thus resulting in a more rigorous vali-
ation of the obtained model. The biological activities
f the compounds used in the test set and predicted using
he MLR model are shown in Tables 3 and 4. The sevenPlease cite this article in press as: E.G. Hadaji, et al. 3D-QSAR mo
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andomly selected compounds of the test set were 3, 6,
0, 11, 14, 25 and 35, and the remaining 39 compounds
ere used as the training set [23,24]. Several statistical
arameters such as the regression coefficient (R), squared– – 6.59
correlation coefficient (R2), adjusted squared correlation
coefficient (R2adj), the Mean Squared Error (MSE), the
Mean Absolute Error (MAE), Fischer’s value (F) and
the significance level (p) < 0.05 were used to validate the
obtained model. A strong QSAR model is characterized
by a large F value, a small MSE value, a very small
p-value, and R and R2 values close to one [25].
2.3.  Calculation  of  molecular  descriptors
First, it was necessary for us to establish several differ-
ent descriptors to evaluate in our model, because in many
cases, the mechanisms that determine the activity and/or
properties of a molecule are poorly understood. Thus, it
is critical to select molecular descriptors that will be most
pertinent to determining the structure–activity relation-
ship of a given molecule. This selection was performed
using MLR analysis.dels to predict anti-cancer activity on a series of protein P38
g/10.1016/j.jtusci.2016.05.006
The forty-six molecules were optimized by means of
quantum mechanics using HF/(6-31G) level completed
in the Gaussian 03 software. A number of electronic
descriptors were later calculated from the optimized
 IN+Model
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molecules, including the dipole moment (DM), orbital
border energy (EHOMO, ELUMO), total energy (Etotal),
electronic repulsion, electronegativity, electronic affin-
ity, hardness and softness.
ChemBioOffice (2012) was used to calculate the
following parameters: partition coefficient (log P),
molecular weight (MW), ovality, cluster count, elec-
tronic energy, solubility coefficient (Log(S)), Connolly
accessible area (CCA), van der Waals energy (E VDW),
torsion energy, H bond donors, H bond acceptors and
molar mass (MM) (Table 2).
2.4.  Statistical  analysis
To analyze the structure–activity relationship for the
46 molecules selected, 22 descriptors were calculated
using the Gaussian 03 and Chemoffice2012 software.
The study director consists of:
Multiple linear regression is a statistical technique
used to study the relationship between one dependent
variable and several independent variables that minimi-
zes the difference between actual and predicted values.
MLR can also be used to select descriptors to be used
as input parameters in MNLR PLS and ANN. Multiple
linear regression, partial least squares (PLS) and multi-
ple non-linear regression models (MLR) were generated
to predict anticancer activities and pIC50 [26–29] using
the software XLSTAT (2015 version) [30] and the ANN
was generated using the software Matlab.
Partial Least Squares regression (PLS) is an efficient
method to identify criteria based on covariance. It is rec-
ommended in cases where the number of variables is
high and where it is likely that the explanatory variables
are correlated.
We also used multiple non-linear regression to
improve our prediction of the structure-function relation-
ship and to quantify the substituting effect. We applied
to the data matrix formed clearly from the descriptors
proposed by MLR corresponding to the 39 molecules
(training set). The coefficients R, R2, and F-values were
used to select the best regression performance. We used
the programmed function of XLSTAT following:
Y  =  a +  (bX1 +  cX2 +  dx3 +  eX4 +  · ·  ·)
+ (fX21 +  gX22 +  hX23 +  iX24 +  · ·  ·)
where a, b, c, d represent the parameters and X1, X2, X3,
X4 represent the variables.Please cite this article in press as: E.G. Hadaji, et al. 3D-QSAR mo
MAP kinase inhibitors, J. Taibah Univ. Sci. (2016), http://dx.doi.or
All feed-forward ANNs used in this paper are three-
layer networks in which the first (input) layer includes six
neurons that represent the pertinent descriptors obtained
using MLR [31]. Though there are neither theoretical PRESS
rsity for Science xxx (2016) xxx–xxx
nor empirical rules to definitively determine the number
of quiet layers or the number of neuron layers required
to generate an optimal ANN, one hidden layer seems
to be sufficient for most chemical applications of ANN.
Some authors [27,32] have offered a parameter   to be
used to calculate the optimal number of hidden neurons,
which plays a major role in determining the best ANN
architecture. ρ  is defined as follows:
ρ  =  (Number of data points in the training set/
Sum of the number of connections in the ANN).
Therefore, in order to avoid overfitting or underfitting,
it is recommended to take into consideration the ρ  value,
which should fall within the range of 1.8 < ρ  < 2.3 [33].
The ANN used in this work was formed by two hidden
neurons, and the output layer represented the calculated
activity values (pIC50).
The cross-validation technique, one of the most
widely used methods for determining the reliability of
statistical model, is based on criteria first defined by
Srone [34]. Based on these criteria, a number of mod-
ified data sets are created by deleting in each case
one or a small group of molecules. These procedures
are called, respectively, “leave-one-out” and “leave-
some-out”. This technique may be particularly useful
when making predictions (or, similarly, estimating the
unknown regression function) is the aim of the statistical
analysis [35].
An additional procedure called “scrambling” must be
used to validate the built model and to verify its simplic-
ity. In certain cases, a model may perform worse on the
test set despite the fact that it does not surapprentissage.
These cases can be explained by obtaining incidental
called model. To exclude the possibility of chance cor-
relation in a model, a technique called scrambling or
Y-randomization may be used [36].
3.  Results  and  discussion
3.1.  Data  set  for  analysis
QSAR was carried out on a series of 46 derivatives
of P38 MAP kinase in order to identify a quantitativedels to predict anti-cancer activity on a series of protein P38
g/10.1016/j.jtusci.2016.05.006
relationship between molecular structure and anti-cancer
activity. The results obtained by 3D-QSAR using the
MLR, PLS, MNLR, ANN and CV analytical methods
are represented in Tables 3 and 4.
Please cite this article in press as: E.G. Hadaji, et al. 3D-QSAR models to predict anti-cancer activity on a series of protein P38
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Table 2
Structures of dataset used for 3D-QSAR analysis of a series of protein P38 MAP kinase inhibitors.
ELUMO EHOMO MD (Debye) I A Electronég Dureté Etotal Log(P) CCA MW
1 1.803 −7.778 5.574 7.7787 −1.803 2.987 4.791 −46593.30 3.642 555.87 401.28
2 1.777 −7.650 6.541 7.6501 −1.777 2.936 4.713 −37881.28 3.076 531.86 385.32
3 1.929 −7.599 6.668 7.5999 −1.929 2.835 4.764 −36915.33 3.697 549.33 383.34
4 1.941 −7.437 7.631 7.4376 −1.941 2.747 4.689 −38400.08 2.592 560.04 398.36
5 1.56 −7.443 5.317 7.4436 −1.526 2.958 4.485 −37937.05 3.796 562.21 395.35
6 1.93 −7.552 6.236 7.5527 −1.973 2.789 4.763 −37968.88 4.115 559.10 397.37
7 2.42 −6.190 10.725 6.1905 −2.442 1.874 4.316 −39393.89 3.49 570.54 402.35
8 2.435 −6.222 10.025 6.222 −2.435 1.893 4.328 −34488.60 1.837 548.716 367.35
9 2.516 −6.132 11.075 6.1327 −2.516 1.808 4.324 −34057.47 3.174 557.57 366.11
10 2.377 −6.176 10.032 6.1765 −2.377 1.899 4.276 −33003.93 3.105 520.31 352.34
11 2.468 −6.125 10.0948 6.1252 −2.468 1.828 4.296 −35111.03 3.454 586.39 380.39
12 2.356 −5.962 10.4827 5.9624 −2.356 1.802 4.159 −34576.34 3.076 594.30 379.41
13 2.156 −6.211 8.3738 6.2110 −2.156 2.027 4.183 −38858.14 3.254 577.44 401.36
14 1.884 −6.495 5.7571 6.4956 −1.884 2.305 4.189 −37805.53 3.044 546.14 387.33
15 2.621 −6.163 11.5199 6.1630 −2.621 1.770 4.392 −33522.48 2.938 564.85 365.38
16 1.852 −6.031 10.1173 6.031 −1.852 2.089 3.941 −37179.98 4.506 583.42 412.44
17 1.874 −6.158 9.1649 6.1587 −1.874 2.142 4.016 −30984.22 2.831 507.90 336.10
18 1.060 −6.285 8.6473 6.285 −1.060 2.612 3.673 −45357.65 3.663 530.08 386.78
19 1.674 −6.269 8.3885 6.269 −1.674 2.297 3.971 −34021.84 3.592 536.02 366.36
20 1.170 −6.168 10.6815 6.168 −1.170 2.498 3.669 −36041.63 2.979 549.17 382.36
21 0.937 −6.373 7.6027 6.373 −0.937 2.717 3.655 −42026.83 4.026 551.03 420.34
22 2.228 −6.239 9.3994 6.239 −2.228 2.005 4.234 −35635.07 3.263 520.27 370.33
23 1.941 −6.222 9.6403 6.222 −1.941 2.140 4.081 −45356.62 3.663 535.14 386.78
24 2.408 −6.111 11.479 6.111 −2.408 1.851 4.260 −34020.99 3.592 544.87 366.36
25 2.554 −6.074 12.9238 6.074 −2.554 1.760 4.314 −36040.61 2.979 559.50 382.36
26 1.105 −6.276 9.0151 6.276 −1.105 2.585 3.690 −42025.59 4.026 563.18 420.34
27 0.760 −6.373 8.3034 6.373 −0.760 2.806 3.567 −35636.27 3.263 519.71 370.33
28 0.837 −6.360 8.6543 6.360 −0.837 2.761 3.598 −45357.73 3.663 534.83 386.78
29 1.645 −6.159 11.4984 6.159 −1.645 2.257 3.902 −34021.95 3.592 542.36 366.36
30 1.117 −6.224 10.2599 6.224 −1.117 2.55 3.670 −36041.58 2.979 557.19 382.36
31 0.804 −6.471 7.9311 6.471 −0.804 2.833 3.637 −42026.99 4.026 561.62 420.34
32 2.232 −6.275 9.7247 6.275 −2.232 2.021 4.253 −38339.93 3.421 526.25 388.32
33 1.929 −6.449 5.3135 6.449 −1.929 2.259 4.189 −48061.48 3.821 537.74 404.77
34 2.196 −6.292 8.5502 6.292 −2.196 2.048 4.244 −48061.55 3.821 540.43 404.77
35 2.189 −6.301 7.9853 6.301 −2.189 2.055 4.245 −48061.59 3.821 537.69 404.77
36 2.203 −6.289 8.714 6.289 −2.203 2.043 4.246 −57782.87 4.221 550.25 421.23
37 2.182 −6.286 9.4028 6.286 −2.182 2.052 4.234 −38340.12 3.421 524.38 388.32
38 1.145 −8.194 9.0994 8.194 −1.145 3.524 4.669 −57787.29 4.221 547.73 421.23
39 2.171 −6.290 9.9216 6.290 −2.171 2.059 4.231 −38340.04 3.421 525.849 388.32
40 1.976 −6.391 9.0384 6.391 −1.976 2.207 4.184 −57783.09 4.221 545.452 421.23
41 1.753 −6.492 7.0462 6.492 −1.753 2.369 4.122 −40970.86 3.579 532.851 406.31
42 1.728 −6.399 7.8184 6.399 −1.728 2.335 4.063 −60414.06 4.38 553.536 439.22
43 1.782 −6.586 5.8516 6.586 −1.782 2.401 4.184 −46343.30 3.896 545.844 442.29
44 1.902 −6.494 4.3506 6.494 −1.902 2.296 4.198 −38340.05 3.421 527.239 388.32
45 1.968 −6.439 4.8976 6.439 −1.968 2.235 4.203 −48061.55 3.821 541.217 404.77
46 1.894 −6.496 4.5246 6.496 −1.894 2.301 4.195 −57782.97 4.221 554.729 421.23
Ovality E VDW Electr E Répulson E Torsion E HB acceptors HB donors Ecart E MMg/mol Cluster c Log S
1.65 4.931 −34157.7 28669.9 0.081 6 0 9.582 401.37 28 −7.3289
1.63 6.146 −35519.7 29905.4 0.337 7 0 9.427 385.07 28 −6.9446
1.46 6.053 −34843.2 29392.6 0.162 4 0 9.529 347.36 26 −6.233
1.64 5.416 −37927.4 32257.4 0.114 5 1 9.379 362.12 27 −6.338
1.65 5.226 −37124 31548.4 0.072 4 0 8.970 359.11 27 −6.819
1.63 7.158 −38042 32435.8 0.201 4 0 9.526 361.12 27 −6.538
1.66 6.300 −37785 31920.8 0.034 8 2 8.632 402.09 29 −6.48
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Table 2 (Continued)
Ovality E VDW Electr E Répulson E Torsion E HB acceptors HB donors Ecart E MMg/mol Cluster c Log S
1.64 6.834 −33210 28222.5 0.035 7 2 8.657 367.11 27 −5.108
1.65 6.657 −33065.2 28142.8 0.031 6 2 8.648 366.11 27 −5.931
1.6 5.456 −31817.7 27051.3 0.0204 6 2 8.553 352.10 26 −5.903
1.67 7.535 −34930.2 29851.9 0.034 6 2 8.593 380.13 28 −6.077
1.68 5.915 −34467.6 29489.7 0.0401 6 3 8.319 379.14 28 −6.104
1.67 4.369 −37586.7 31822.7 0.035 8 3 8.367 401.11 29 −6.504
1.65 3.569 −36064.5 30457 0.052 8 3 8.379 387.09 28 −6.479
1.66 4.731 −32904.9 28082.6 0.030 6 3 8.784 365.13 28 −6.479
1.64 7.671 −40099.4 34830.9 4.873 5 2 7.883 412.13 31 −7.905
1.60 4.132 −29239.4 24793.5 0.0379 5 2 8.032 336.10 25 −5.825
1.61 6.308 −34147 29020.7 0.035 6 2 7.346 386.06 27 −6.581
1.62 6.514 −33994.2 29072 0.043 6 2 7.943 366.11 27 −6.102
1.63 7.618 −36420.1 31178 0.078 7 2 7.339 382.11 28 −5.737
1.63 6.257 −42266.8 35931.3 0.067 9 2 7.310 420.08 30 −6.918
1.61 5.782 −34015.1 28777.8 0.040 7 2 8.468 370.09 27 −6.178
1.62 6.196 −33806.9 28680.4 0.035 6 2 8.163 386.06 27 −6.596
1.63 6.453 −33661.5 28739.3 0.027 6 2 8.520 366.11 27 −6.265
1.65 7.633 −35817.3 30575.1 0.069 7 2 8.628 382.11 28 −5.964
1.65 6.166 −41007 34671.4 0.056 9 2 7.381 420.08 30 −6.914
1.61 5.799 −34023.9 28786.6 0.034 7 2 7.134 370.09 27 −6.168
1.62 6.232 −33758 28631.5 0.041 6 2 7.197 386.06 27 −6.601
1.63 6.395 −33730.9 28808.6 0.056 6 2 7.805 366.11 27 −6.252
1.64 7.603 −35934 30691.9 0.066 7 2 7.341 382.11 28 −5.951
1.65 6.224 −41101.8 34766.1 0.053 9 2 7.275 420.08 30 −6.934
1.61 5.719 −36799.7 31091.7 0.029 8 2 8.507 388.08 28 −6.389
1.62 6.108 −36521.6 30924.4 0.028 7 2 8.379 404.05 28 −6.838
1.62 6.010 −36465.6 30868.3 0.036 7 2 8.489 404.05 28 −6.838
1.62 6.066 −36453.5 30856.2 0.037 7 2 8.491 404.05 28 −6.845
1.62 7.168 −36286.1 30799.8 0.041 6 2 8.493 420.02 28 −7.261
1.61 5.614 −36886.9 31178.8 0.032 8 2 8.469 388.08 28 −6.416
1.62 6.532 −36446.4 30960 0.036 6 2 9.339 420.02 28 −7.275
1.61 5.658 −37224.6 31516.5 0.048 8 2 8.462 388.08 28 −6.387
1.62 6.653 −36487.9 31001.6 0.099 6 2 8.368 420.02 28 −7.257
1.62 5.481 −39681.5 33502.7 0.051 9 2 8.245 406.07 29 −6.654
1.63 6.364 −38777.3 32820.1 0.098 7 2 8.127 438.01 29 −7.519
1.64 5.219 −45261.6 38141.5 0.053 11 2 8.368 442.05 31 −7.117
1.62 5.615 −36418.9 30710.8 0.037 8 2 8.396 388.08 28 −6.416
1.62 6.050 −36219.7 30622.5 0.024 7 2 8.407 404.05 28 −6.847
1.63 6.992 −35914 30427.6 0.057 6 2 8.391 420.02 28 −7.283.2.  Multiple  linear  regressions
In order to select the critical descriptors that affect
the inhibitory activities of these compounds, correla-
tion analysis was performed with the statistical software
XLSTAT using each calculated descriptor as an inde-
pendent variable and pIC50 as a dependent variable. The
aforementioned stepwise multiple linear regression tech-Please cite this article in press as: E.G. Hadaji, et al. 3D-QSAR mo
MAP kinase inhibitors, J. Taibah Univ. Sci. (2016), http://dx.doi.or
nique was used to establish the QSAR model based on
the correlation analysis.
The QSAR model built using multiple linear regres-
sion (MLR) method is represented by the followingequation:
pIC50 =  10.254 +  0.329EHOMO+1.969 ∗  10−4Etotal
−  4.481 ∗  10−2CCA+0.141M
+  2.591 ∗  10−3Electr E+2.263 ∗ 10−3Repul E
(1)
2dels to predict anti-cancer activity on a series of protein P38
g/10.1016/j.jtusci.2016.05.006
n =  39; R  =  0.791; R = 0.615;
R2adjusted =  0.543; F  =  8.537; Pr  <  0.0001;
MAE =  0.281; MSE =  0.144
Please cite this article in press as: E.G. Hadaji, et al. 3D-QSAR models to predict anti-cancer activity on a series of protein P38
MAP kinase inhibitors, J. Taibah Univ. Sci. (2016), http://dx.doi.org/10.1016/j.jtusci.2016.05.006
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Table 3
Observed and predicted activities of statistically significant models obtained by 3D-QSAR training set.
Observation PIC50 Préd(PIC50)
RLM
Préd(PIC50)
RNLM
Préd(PIC50)RN Préd(PIC50)CV Observation PIC50 Préd(PIC50)
PLS
Mol1 6.490 6.553 6.322 6.3980 6.31 1 6.490 6.712
Mol2 6.720 6.403 6.393 6.8207 6.6 2 6.720 6.681
Mol4 6.060 6.031 6.089 5.7856 6.1 4 6.060 6.022
Mol5 6.050 6.076 6.157 6.0523 6.42 5 6.050 6.044
Mol7 6.140 5.945 6.121 5.9959 6.1 6 6.310 5.988
Mol8 6.300 6.431 6.257 6.6008 6.52 7 6.140 6.111
Mol9 5.890 6.168 5.986 6.0306 5.88 9 5.890 6.541
Mol12 5.840 5.764 5.708 5.6912 5.59 10 6.800 7.232
mol13 5.800 5.887 6.005 6.0019 5.88 11 6.320 5.923
mol15 6.140 6.113 5.932 6.0534 6.28 12 5.840 5.838
Mol16 7.700 7.867 7.620 7.5618 7.01 13 5.800 5.985
Mol17 6.190 7.093 6.178 6.1654 6.51 15 6.140 6.404
Mol18 7.360 7.221 7.385 7.3689 7.48 18 7.360 7.300
Mol19 7.040 6.827 7.089 7.1056 6.96 19 7.040 6.787
mol20 7.090 6.608 6.901 6.7754 7.06 20 7.090 6.436
mol21 5.620 6.239 5.734 5.9594 5.77 21 5.620 6.085
mol22 6.380 7.064 7.049 6.5555 6.67 22 6.380 7.138
mol23 6.620 7.127 7.173 6.5745 6.75 23 6.620 7.261
Mol24 7.150 6.592 6.762 6.8035 6.7 24 7.150 6.696
Mol26 6.100 6.140 6.295 6.1803 6.16 25 6.350 6.340
Mol27 7.320 7.041 6.975 7.3169 7.31 27 7.320 7.126
Mol28 7.100 7.111 7.081 7.1563 7.05 28 7.100 7.249
Mol29 6.590 6.665 6.854 6.9186 6.71 29 6.590 6.724
Mol30 6.300 6.390 6.583 6.4783 6.43 30 6.300 6.343
mol31 6.000 6.114 6.161 6.0985 6.13 31 6.000 6.014
mol32 7.490 6.808 7.030 7.2747 7.23 32 7.490 6.886
mol33 7.490 6.983 7.255 7.4910 7.16 33 7.490 7.043
Mol34 7.960 6.932 7.241 7.4694 7.22 34 7.960 7.028
Mol36 7.520 7.208 7.061 7.3613 7.44 35 7.850 7.075
Mol37 6.890 6.859 7.092 7.3359 6.82 36 7.520 7.231
Mol38 6.550 6.640 6.774 6.6732 6.7 37 6.890 6.907
Mol39 7.020 6.681 6.891 6.8863 7.11 39 7.020 6.845
Mol40 7.050 7.324 7.187 7.4146 6.97 40 7.050 7.275
Mol41 6.700 6.448 6.569 6.3663 6.76 41 6.700 6.581
mol42 7.170 7.160 7.222 7.1719 7.13 42 7.170 7.042
mol43 5.370 5.888 5.237 5.3260 5.9 43 5.370 6.053
Mol44 6.570 6.817 6.925 6.5082 6.48 44 6.570 6.875
Mol45 6.850 6.930 7.156 6.9255 6.67 45 6.850 7.018
Mol46 6.590 7.062 6.761 6.5567 6.61 46 6.590 7.162
Table 4
Observed and predicted activities of statistically significant models obtained by 3D-QSAR test set.
Observation PIC50 test Pred PIC50 RLM test Pred PIC50 RNLM test Observation PIC50 Pred PIC50 PLS test
3 7.030 6.141 5.952 3 7.030 6.418
6 6.310 6.087 6.155 8 6.300 6.683
10 6.800 6.851 6.692 14 5.890 6.565
11 6.320 5.720 5.647 16 7.700 5.578
14 5.890 6.279 6.253 17 6.190 7.604
25 6.350 6.374 6.619 26 6.100 6.029
35 7.850 7.056 7.386 38 6.550 6.953
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Fig. 1. Anti-cancer activities predicted by MLR in comparison with
experimental values.
As indicated in the above equation, the most signifi-
cant descriptors affecting anti-cancer activity of the P38
MAP kinase derivatives studied were electronic descrip-
tors (Electr E, repulsion E, total E  and EHOMO) and steric
descriptors (MW, CCA).
The applicability domain of a QSAR model is a theo-
retical region in chemical space encompassing both the
model descriptors and modeled response. This domain
allows an estimation of uncertainty in the prediction
of a particular compound based on its similarity to the
training compounds employed in the development of the
model. This domain is also used to define the X-outliers
(in case of the training set) and to identify the compounds
residing outside the applicability domain (in case of the
test set) employing the basic theory of the standardiza-
tion approach. The applicability domain is an important
tool for reliable application of QSAR models, and the
characterization of interpolation space is significant in
defining the applicability domain [37].
In this study, we use the standardization approach
introduced by Roy et al. to determine the application
domain of our QSAR model [38]. This approach is used
to define outliers (in case of the training set) and the
compounds residing outside the applicability domain (in
case of the test set) of the built QSAR model. All results
are tabulated in Tables S1 and S2 in the Supplementary
Materials. As shown in Table S1, all compounds within
the training set were considered non-outliers and all test
compounds were shown to be inside the applicabilityPlease cite this article in press as: E.G. Hadaji, et al. 3D-QSAR mo
MAP kinase inhibitors, J. Taibah Univ. Sci. (2016), http://dx.doi.or
domain of the QSAR model obtained.
The observed versus predicted values for all training
and test set compounds are shown graphically in Fig. 1.Fig. 2. Graphical representation of calculated and observed activity by
PLS.
The correlation between experimental and calculated
activity based on this model was highly significant for
our set of 46 compounds (Fig. 2) as indicated by statis-
tical analysis:
Where n  is the number of compounds, r is the correla-
tion coefficient, F  is the Fisher F-statistic, MSE is mean
square error.
Several statistical parameters such as regression coef-
ficient (R), square correlation coefficient (R2), adjusted
square correlation coefficient (R2adj), standard error of
estimate (S), Fischer’s value (F) and significance level
(p) < 0.005 were used to verify the credibility of the
developed model.
Generally, a good QSAR model has the following
characteristics: a large F, a small MSE, a very small
p value, and R2 and R2adjuted values close to one. Eq.
(1) satisfied these criteria and was therefore statisti-
cally acceptable. The F-test was also used. Given that
the probability corresponding to the F value was lower
than 0.05 for anti-cancer activity, there is a lower than
<0.01% risk that the null hypothesis is false. There-
fore, we can conclude with confidence that the model
will correctly predict the anti-cancer activity of a given
compound.
Descriptors that influence anti-cancer activity and
show high values of their coefficient increase anti-cancer
activity (pIC50). pIC50 changes with the values of the
descriptor coefficients, as shown in Eq. (1). The EHOMO,
the repulsion energy, the electronic energy, the molecu-dels to predict anti-cancer activity on a series of protein P38
g/10.1016/j.jtusci.2016.05.006
lar weight and total energy are directly proportional to
the pIC50, whereas CCA is inversely proportional to the
pIC50.
 IN PRESS+ModelJ
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Table 5
Comparison between coefficients statistically significant models
obtained by 3D models test set.ARTICLETUSCI-311; No. of Pages 16
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The correlation between the experimental plots
nd data predicted using multiple regression given in
ables 3 and 4 demonstrates that values predicted by
his model are close to those obtained experimentally.
his result demonstrated that the model developed in this
ork can be successfully used to predict whether a given
38 MAP kinase inhibitor would have anti-cancer activ-
ty. Fig. 1 shows a regular distribution of an anti-cancer
ctivity values based on the observed and experimental
alues.
.3.  Partial  least  squares  (PLS)
PLS analysis has two objectives: to approximate the
atrix X of molecular structure descriptors to the matrix
 of dependent variables and to maximize the correlation
etween them.
We created a data matrix corresponding to the 39
olecules from the descriptors selected by MLR for the
artial least squares (PLS) approach. This method used
he coefficients R, R2, and the F-values to select the best
egression performance.
The molecular descriptors used were total energy,
nergy EHOMO, CCA, MW, the electronic energy and
epulsion energy. To correlate the molecule descriptors
inearly to pI50, the following equation was used:
IC50 =  18.427EHOMO −  3.349 ∗  10−5Etotal
−  1.706 ∗  10−2CCA +  1.942 ∗  10−3MW
+ 4.713 ∗  10−5Electr E−6.001 ∗  10−5Repul E
(2)
N =  39 R2 =  0.579 R  =  0.762; MAE =  0.374,
MSE =  0.269
Fig. 2 shows a regular distribution of activity values
epending on the experimental values.
The obtained coefficient of correlation in Eq. (2)
as relatively high (0.762). Identifying compounds with
mproved anti-cancer activity can be approached in a
uantitative manner, taking into account several parame-
ers; in this work, we used the technique of the non-linear
egression model.
.4.  Multiple  non-linear  regressionPlease cite this article in press as: E.G. Hadaji, et al. 3D-QSAR mo
MAP kinase inhibitors, J. Taibah Univ. Sci. (2016), http://dx.doi.or
The basic descriptors correspond to the MLR; 39
ompounds were applied to the data matrix. The
oefficients R, R2, and the mean squared error (MSE)MLR MNLR
N = 7, R = 0.7 N = 7, R = 0.67
were used to select the best performance of the regres-
sion.
The resulting equations:
PIC50 =  31.657 +  4.669EHOMO −  1.476 ∗  10−4Etotal
+  5.763 ∗ 10−4CCA −  0.24MW
+ 9.836 ∗ 103Electr E  +  1.39 ∗  10−2Repul E
+ 0.309(EHOMO)2 −  4.629 ∗  10−9(Etotal)2
−  5.108 ∗ 105(CCA)2 + 5.313 ∗  10−4(MW)2
+  8.69024769889427 ∗  10−8(Electr E)2
−  1.732 ∗  107(Repul E)2 (3)
N =  39,  R  =  0.89,  R2 =  0.797 MSE =  0.076
MAE =  0.215
Before performing external validation of the obtained
QSAR model, the Xternal Validation tool proposed by
Roy et al. [39] was used to check for systematic error that
would violate the basic assumptions of the least squares
regression model. All results are listed in Snapshots 1
and 2 in the Supplementary Materials. If high system-
atic error (bias) is present in the model, then such a
model should be discarded, and performing any external
validation test would be useless. The obtained MAE-
based metric estimated using the above approach was
0.2438 (MAE = 0.2438), indicating that the model pro-
vides highly accurate predictions of anticancer activity
of P38 kinases.
To confirm this result, external validation has been
carried out using Eq. (2).
The predicted values of pIC50 calculated from Eq. (2)
are listed in Table 4 alongside the observed values. The
correlation between predicted and observed activities is
shown in Fig. 3.
MLR and MNLR analyses were validated by dividing
the data set into the training and the test set. The exter-
nal validation of several correlation coefficients weredels to predict anti-cancer activity on a series of protein P38
g/10.1016/j.jtusci.2016.05.006
(pIC50 = 0.7) MLR and R (pIC50) = 0.67 MNLR for the
whole test (Table 5).
The correlation coefficient obtained from Eq. (2)
was relatively high (0.891), indicating that the toxicity
ARTICLE IN PRESS+ModelJTUSCI-311; No. of Pages 16
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Our QSAR model includes several molecular
descriptors, and regression quality indicates that these
descriptors provide valuable information for assessing
5,5
6,0
6,5
7,0
7,5
8,0
Y=1.1X-1.1
P
IC
50
N=39        R= 0.925         SD=0.238      P<0.00 01      Fig. 3. Graphical representation of calculated and observed pIC50 with
MNLR (training set in blue, test set in red).
values predicted using non-linear regression were highly
correlated with those observed experimentally.
3.5.  Artiﬁcial  Neural  networks
To increase the probability of good characteriza-
tion of compounds, artificial neural networks (ANN)
can be used to generate predictive models of quanti-
tative structure–activity relationships (QSAR) between
a set of molecular descriptors obtained from the MLR
and observed activity. The correlation of the observed
activities with those calculated using ANN are illus-
trated in Fig. 4. The correlation coefficient (R  = 0.942)
and Standard Deviation (SD = 0.211), obtained with the
ANN indicate that the descriptors selected by MLR are
pertinent and that the model proposed to predict anti-
cancer activity is relevant.
N  =  39 R  =  0.942,  MSE =  0.042,
MAE =  0.158,  SD =  0.211 P <  0.0001
3.6.  Validation
To validate our results, we used the “leave-one-out”
procedure, which involves removing a single moleculePlease cite this article in press as: E.G. Hadaji, et al. 3D-QSAR mo
MAP kinase inhibitors, J. Taibah Univ. Sci. (2016), http://dx.doi.or
from the set containing 39 molecules and making a pre-
diction for the molecule that was left out. This procedure
is repeated 39 times in order to predict the properties of
all the molecules.Fig. 4. The correlation between Observed pIC50 and pIC50 predicted
by ANN.
The consistency and reliability of the MLR and
ANN models were validated using the cross-validation
technique. A good correlation was obtained with cross
validation Rcv = 0.925, indicating that this model has sig-
nificant predictive power (Fig. 5).
N  =  39; R =  0.925; SD =  0.238 P  <  0.0001
The most important finding from this investigation
is that in vitro anti-cancer activity may be predicted
using QSAR methods. Our results affirm that the arti-
ficial neural network was the best foundation on which
to build the quantitative structure–activity relationship
model and that the model proposed in this study has
high predictive power (RANN = 0.94).dels to predict anti-cancer activity on a series of protein P38
g/10.1016/j.jtusci.2016.05.006
5,5 6,0 6,5 7,0 7,5
5,0
Predit(PIC50)
Fig. 5. Correlation between Obs pIC50 and pIC50 CV.
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Table 6
Comparison between observed and predicted activities obtained using the scrambling method.
Compound
3 15 5 6 8 9 10 11 12 22 16 18 19 20 35 21 23 24 25 26
pIC50 7.03 6.14 6.05 6.31 6.3 5.89 6.8 6.32 5.84 6.38 7.7 7.36 7.04 7.09 7.85 5.62 6.62 7.15 6.35 6.1
pIC50 prd 6.56 6.25 6.74 6.28 6.19 5.98 6.94 6.22 5.93 6.44 7.62 7.23 7.07 6.88 7.69 6.27 6.6 6.81 6.33 6.12
Compound
1 2 27 28 29 42 30 32 34 37 38 39 40 43 44 45 46 33 36
p 7.96 6.89 6.55 7.02 7.05 5.37 6.57 6.85 6.59 7.49 7.52
p 7.23 7.04 6.67 7.01 6.96 5.6 6.65 6.79 6.77 7.4 7.16
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C5
0IC50 6.49 6.72 7.32 7.1 6.59 7.17 6.3 7.49 
IC50 prd 6.52 6.87 7.23 7.18 6.59 7.14 6.32 7.08 
he activity of P38 MAP kinases. The artificial neural net-
ork (ANN) technique, which considered the relevant
escriptors obtained from the MLR analysis, showed
ood agreement between the observed and the predicted
alues and the model obtained was confirmed by the
OO cross-validation method.
.7.  Scrambling  or  Y-randomization
Y-randomization is widely used in QSAR studies to
nsure the robustness of obtained models. This method is
sed after the “best” regression model is selected to make
ure that there are no chance correlations. Scrambling
alidates the QSAR model by comparing the perfor-
ance of the original model to that of models built
or permuted (randomly shuffled) responses based on
he original descriptor pool and the original procedure
sed to build the model. If the correlation coefficient
f models built for permuted responses is close to that
btained by applying the full model, this result indicates
hat there is independence between the molecules, as the
earest target point measurement points do not obscure
ther experimental data and are not almost exclusively
nvolved in the estimate, and the data used in this vali-
ation are evenly distributed in space. Therefore, the
esulting model can be extrapolated to the entire series
40] (Table 6 and Fig. 6).
 =  39; R  =  0.922; SD =  0.232; P  <  0.0001
The correlation coefficient value of the mixture of
olecules was close to that obtained by applying the
ull model. This result demonstrates the absence of
ependence between descriptors included in the model.
dditionally, the closest measurement point of the tar-Please cite this article in press as: E.G. Hadaji, et al. 3D-QSAR mo
MAP kinase inhibitors, J. Taibah Univ. Sci. (2016), http://dx.doi.or
et point does not hide other experimental data and is not
nvolved exclusively in the estimate, and the data used
n this validation are regularly distributed in space so the
esulting model can be extrapolated for the entire series.pIC50 Pr ed
Fig. 6. Correlation between ObspIC50 and pIC50 scrambling.
3.8.  Lipinski’s  Rule  of  Five
According to the following empirical principles enun-
ciated by Christopher Lipinski as the “Rule of Five”
[41], a rule that is used in the characterization of drug-
like compounds [42], a substance will be achieve better
absorption or penetration if:
1. Its molecular weight is less than or equal to 500 Da.
2. It has 5 or fewer hydrogen bond donors (sum of OH
and NH).
3. It has 10 or fewer hydrogen bond acceptors (sum of
O and N).
4. Its log P  value is less than or equal to 5.
Conditions that satisfy Lipinski’s rules result in good
oral bioavailability, which involves a balance between
a compound’s aqueous solubility and its ability to pas-dels to predict anti-cancer activity on a series of protein P38
g/10.1016/j.jtusci.2016.05.006
sively diffuse through various biological barriers [43,44].
Molecules that violate more than one of these
rules may have problems with bioavailability. Lipin-
ski’s rules establish structural parameters that enable
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Table 7
Violations of rule Lipinski.
Log(P) HB acceptors HB donors MM No. of violation
1 3.642 6 0 401.37861 0
2 3.076 7 0 385.07259 0
3 3.697 4 0 347.3648 0
4 2.592 5 1 362.12307 0
5 3.796 4 0 359.11217 0
6 4.115 4 0 361.12782 0
7 3.49 8 2 402.09914 0
8 1.837 7 2 367.11323 0
9 3.174 6 2 366.11798 0
10 3.105 6 2 352.10233 0
11 3.454 6 2 380.1336 0
12 3.076 6 3 379.14961 0
13 3.254 8 3 401.11512 0
14 3.044 8 3 387.09947 0
15 2.938 6 3 365.1339 0
16 4.506 5 2 412.1387 0
17 2.831 5 2 336.10741 0
18 3.663 6 2 386.06336 0
19 3.592 6 2 366.11798 0
20 2.979 7 2 382.11289 0
21 4.026 9 2 420.08971 0
22 3.263 7 2 370.09291 0
23 3.663 6 2 386.06336 0
24 3.592 6 2 366.11798 0
25 2.979 7 2 382.11289 0
26 4.026 9 2 420.08971 0
27 3.263 7 2 370.09291 0
28 3.663 6 2 386.06336 0
29 3.592 6 2 366.11798 0
30 2.979 7 2 382.11289 0
31 4.026 9 2 420.08971 0
32 3.421 8 2 388.08349 0
33 3.821 7 2 404.05393 0
34 3.821 7 2 404.05393 0
35 3.821 7 2 404.05393 0
36 4.221 6 2 420.02438 0
37 3.421 8 2 388.08349 0
38 4.221 6 2 420.02438 0
39 3.421 8 2 388.08349 0
40 4.221 6 2 420.02438 0
41 3.579 9 2 406.07406 0
42 4.38 7 2 438.01496 0
43 3.896 11 2 442.05522 1
44 3.421 8 2 388.08349 0
45 3.821 7 2 404.05393 0
2 46 4.221 6 
theoretical prediction of oral bioavailability profiles of
given molecules and are thus widely used in drug design.
Our calculations (Table 7) demonstrated that all com-
pounds satisfied Lipinski’s rules, which suggests thatPlease cite this article in press as: E.G. Hadaji, et al. 3D-QSAR mo
MAP kinase inhibitors, J. Taibah Univ. Sci. (2016), http://dx.doi.or
none of them should have problems with oral bioavail-
ability (with the possible exception of molecule 43,
which has 11 acceptor sites).420.02438 0
4.  Conclusions
A quantitative analysis of the structure-property
relationship (QSAR) was performed on 46 moleculesdels to predict anti-cancer activity on a series of protein P38
g/10.1016/j.jtusci.2016.05.006
derived from P38 MAP kinases. A QSAR model
was established using the Multiple Linear Regres-
sion (MLR), Partial Least Squares (PLS), Multiple
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Assessing the quality of the MLR and ANN models
as revealed that the predictive capability of ANN was
ubstantially better than that of the other methods.
The predictive power of the model obtained was con-
rmed by LOO cross-validation. A strong correlation
as observed between the experimental and predicted
alues of the biological activities, which indicated the
alidity and quality of the QSAR model developed in this
ork. Finally, we conclude that the descriptors studied
e.g., EHOMO and Etotal), which influenced the structural
eatures of the P38 MAPK analogs we examined, can be
sed in tandem with other topological descriptors for the
evelopment of predictive QSAR models.
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.jtusci.2016.05.006.
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